Category: harvard

Second retraction by Harvard group studying cannabinoids, this one in JBC

Last week, we reported that a group of Harvard researchers had retracted a paper in Blood for “multiple instances of duplicate (redundant) publication of data, text, and images that are nonessential to the paper.” The retraction notice referred to a paper in the Journal of Biological Chemistry (JBC):

The redundancies are between the above-cited Blood article and the following 12 November 2010 article, published in the Journal of Biological Chemistry (JBC): Jiang S, Zagozdzon R, Jorda MA, et al. Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment. J Biol Chem. 2010;285(46):35471-35478.

Today, we learned that the JBC paper has also been retracted. The notice, as we’ve come to expect from the JBC, is unhelpful: Continue reading Second retraction by Harvard group studying cannabinoids, this one in JBC

“Nonessential” duplication leads to retraction of Blood cannabinoid paper

The journal Blood has retracted a paper from a group of prestigious Harvard researchers after the article, which appeared in January 2011, was found to have multiple instances of material — text, data and other elements — that had appeared in a previous publication from several of the authors.

The article was titled “Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization.” Its authors included Hava Avraham, a noted cancer researcher, and Jerome Groopman, known for his New Yorker articles about medicine and, scientifically, for his work on cannabinoids and cancer, among other areas.

According to the retraction notice: Continue reading “Nonessential” duplication leads to retraction of Blood cannabinoid paper

Science publishes replication of Marc Hauser study, says results hold up

There has been some news over the past few weeks about Marc Hauser, the Harvard psychologist found guilty of misconduct by the university last year. First, because Harvard had listed him in a course catalog, The Crimson said that he might be teaching again, following a ban. But that turned out not to be the case, as The Boston Globe reported.

Today, Science lifted the embargo on a paper by Hauser and Justin Wood, now of the University of Southern California, showing that results published in the journal in 2007 — and later questioned — have held up. The abstract: Continue reading Science publishes replication of Marc Hauser study, says results hold up

In a retraction’s wake: Postdoc Shane Mayack, dismissed from Amy Wagers’ stem cell lab, speaks out

 

Last October, Retraction Watch readers will recall, up-and-coming stem cell researcher Amy Wagers retracted a study in Nature describing how her team rejuvenated blood-forming stem cells in older mice. Shane Mayack, a postdoc in Wagers’ lab who had been dismissed after an inquiry into what happened, did not sign that retraction. Since then, Mayack has not spoken to the press, except for a brief comment to Nature through her attorney.

Here, we present, unedited, Mayack’s side of the story. While accepting responsibility, she also has a number of suggestions for how universities and journals can handle these situations better. Shane can be reached at smayck[at]yahoo.com.

Since it was well covered by this blog, the readers of Retraction Watch are no doubt aware that in October 2010, a paper that I co-authored was retracted from Nature and a notice of concern was posted regarding a second paper published in Blood.

So, what went wrong? Continue reading In a retraction’s wake: Postdoc Shane Mayack, dismissed from Amy Wagers’ stem cell lab, speaks out

Scientist raised serious questions about 2008 Cell study by Amy Wagers

Amy Wagers, a Harvard stem cell researcher, retracted a Nature study last week and has another published paper under scrutiny at Blood. Retraction Watch has now learned that a 2008 Cell paper she co-authored drew significant criticism from a stem cell researcher at Children’s National Medical Center.

In the paper, Wagers and her team said they were able to prepare a set of muscle cells that reversed some of the effects of muscular dystrophy in a mouse model of the disease. In a 2008 letter to the editor of Cell, however, Terence Partridge wrote Continue reading Scientist raised serious questions about 2008 Cell study by Amy Wagers

Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Yesterday, we noted that Amy Wagers and Shane Mayack have published five papers together. One of those, published earlier this year in Nature, was retracted Wednesday, and another is now the subject of a “notice of concern” from Blood.

We wanted to find out about some of the other papers published by Wagers and Mayack, so we contacted the editor of Developmental Biology, which published one of them. They have not heard from Wagers or Harvard, but are monitoring developments, according to editor in chief Robb Krumlauf: Continue reading Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Blood posts “notice of concern” over second Wagers-Mayack paper

A day after an up and coming Harvard stem cell scientist retracted a Nature paper, Blood has issued a notice of concern about another paper by the same group, published in August 2008, the Boston Globe reports. Such notices often, but not always, precede retractions.

According to the notice for “Osteolineage niche cells initiate hematopoietic stem cell mobilization”: Continue reading Blood posts “notice of concern” over second Wagers-Mayack paper

Highly cited Harvard stem cell scientist retracts Nature paper

courtesy Nature

Amy Wagers, an up and coming stem cell researcher at Harvard who made a name for herself as a postdoc early by questioning the work of others, has retracted a January 2010 paper she co-authored in Nature. According to the retraction:

Three of the authors (J.L.S., F.S.K. and A.J.W.) wish to retract this Article after a re-examination of the publication raised serious concerns with some of the reported data. These concerns have undermined the authors’ confidence in the support for the scientific conclusions reported, specifically the role of osteopontin-positive niche cells in the rejuvenation of haematopoietic stem cells in aged mice. Although this matter is under further review, these authors wish to retract the paper in its entirety, and regret any adverse consequences that may have resulted from the paper’s publication. The retraction has not been signed by Shane R. Mayack, who maintains that the results are still valid.

Monkey business? 2002 Cognition paper retracted as prominent psychologist Marc Hauser takes leave from Harvard

Marc Hauser, a prominent Harvard psychology researcher and author, will be taking a leave of absence from the university following “a lengthy internal investigation found evidence of scientific misconduct in his laboratory” that has led to the retraction of one of his papers, according to The Boston Globe.

The retraction, of a 2002 paper in Cognition, reads, in part: “An internal examination at Harvard University . . . found that the data do not support the reported findings. We therefore are retracting this article,” the Globe reports.  It also includes the sentence “MH accepts responsibility for the error.”

The retraction notice does not yet appear anywhere on the journal’s site, where the PDF version of the study is still available, nor on the Medline abstract. Its circumstances appear to be atypical, according to the Globe: Continue reading Monkey business? 2002 Cognition paper retracted as prominent psychologist Marc Hauser takes leave from Harvard